Show simple item record

Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis

dc.contributor.authorLarkin, James
dc.contributor.authorChmielowski, Bartosz
dc.contributor.authorLao, Christopher D.
dc.contributor.authorHodi, F. Stephen
dc.contributor.authorSharfman, William
dc.contributor.authorWeber, Jeffrey
dc.contributor.authorSuijkerbuijk, Karijn P. M.
dc.contributor.authorAzevedo, Sergio
dc.contributor.authorLi, Hewei
dc.contributor.authorReshef, Daniel
dc.contributor.authorAvila, Alexandre
dc.contributor.authorReardon, David A.
dc.date.accessioned2017-12-15T16:48:26Z
dc.date.available2018-08-07T15:51:22Zen
dc.date.issued2017-06
dc.identifier.citationLarkin, James; Chmielowski, Bartosz; Lao, Christopher D.; Hodi, F. Stephen; Sharfman, William; Weber, Jeffrey; Suijkerbuijk, Karijn P. M.; Azevedo, Sergio; Li, Hewei; Reshef, Daniel; Avila, Alexandre; Reardon, David A. (2017). "Neurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis." The Oncologist 22(6): 709-718.
dc.identifier.issn1083-7159
dc.identifier.issn1549-490X
dc.identifier.urihttps://hdl.handle.net/2027.42/139998
dc.description.abstractBackgroundDespite unprecedented efficacy across multiple tumor types, immune checkpoint inhibitor therapy is associated with a unique and wide spectrum of immune‐related adverse events (irAEs), including neurologic events ranging from mild headache to potentially life‐threatening encephalitis. Here, we summarize neurologic irAEs associated with nivolumab and ipilimumab melanoma treatment, present cases of treatment‐related encephalitis, and provide practical guidance on diagnosis and management.MethodsWe searched a Global Pharmacovigilance and Epidemiology database for neurologic irAEs reported over an 8‐year period in patients with advanced melanoma receiving nivolumab with or without ipilimumab from 12 studies sponsored by Bristol‐Myers Squibb. Serious neurologic irAEs were reviewed, and relationship to nivolumab or ipilimumab was assigned.ResultsIn our search of 3,763 patients, 35 patients (0.93%) presented with 43 serious neurologic irAEs, including neuropathy (n = 22), noninfective meningitis (n = 5), encephalitis (n = 6), neuromuscular disorders (n = 3), and nonspecific adverse events (n = 7). Study drug was discontinued (n = 20), interrupted (n = 8), or unchanged (n = 7). Most neurologic irAEs resolved (26/35 patients; 75%). Overall, median time to onset was 45 days (range 1–170) and to resolution was 32 days (2–809+). Median time to onset of encephalitis was 55.5 days (range 18–297); four cases resolved and one was fatal.ConclusionBoth oncologists and neurologists need to be aware of signs and symptoms of serious but uncommon neurologic irAEs associated with checkpoint inhibitors. Prompt diagnosis and management using an established algorithm are critical to minimize serious complications from these neurologic irAEs.Implications for PracticeWith increasing use of checkpoint inhibitors in cancer, practicing oncologists need to be aware of the potential risk of neurologic immune‐related adverse events and be able to provide prompt treatment of this uncommon, but potentially serious, class of adverse events. We summarize neurologic adverse events related to nivolumab alone or in combination with ipilimumab in patients with advanced melanoma from 12 studies and examine in depth 6 cases of encephalitis. We also provide input and guidance on the existing neurologic adverse events management algorithm for nivolumab and ipilimumab.Melanoma is a particularly immunogenic cancer, and immune checkpoint inhibitors have been extensively studied in this tumor type. This review focuses on the incidence of serious neurologic immune‐related adverse events, specifically encephalitis, in patients with advanced melanoma treated with nivolumab alone or in sequence or combination with ipilimumab. Practical guidance is provided for the diagnosis and management of treatment‐related encephalitis associated with nivolumab and ipilimumab.
dc.publisherWiley Periodicals, Inc.
dc.subject.otherCase series
dc.subject.otherMelanoma
dc.subject.otherImmune‐related adverse events
dc.subject.otherNeurologic adverse events
dc.subject.otherEncephalitis
dc.subject.otherImmune checkpoint inhibitors
dc.titleNeurologic Serious Adverse Events Associated with Nivolumab Plus Ipilimumab or Nivolumab Alone in Advanced Melanoma, Including a Case Series of Encephalitis
dc.typeArticleen_US
dc.rights.robotsIndexNoFollow
dc.subject.hlbsecondlevelHematology and Oncology
dc.subject.hlbtoplevelHealth Sciences
dc.description.peerreviewedPeer Reviewed
dc.description.bitstreamurlhttps://deepblue.lib.umich.edu/bitstream/2027.42/139998/1/onco12130.pdf
dc.identifier.doi10.1634/theoncologist.2016-0487
dc.identifier.sourceThe Oncologist
dc.identifier.citedreferenceTunkel AR, Glaser CA, Bloch KC et al. The management of encephalitis: Clinical practice guidelines by the Infectious Diseases Society of America. Clin Infect Dis 2008; 47: 303 – 327.
dc.identifier.citedreferenceIbrahim RA, Berman DM, DePril V et al. Ipilimumab safety profile: Summary of findings from completed trials in advanced melanoma. J Clin Oncol 2011; 29 ( suppl ): 8583a.
dc.identifier.citedreferenceOPDIVO® (nivolumab) [package insert]. Princeton, NJ: Bristol‐Myers Squibb Company USA; 2016.
dc.identifier.citedreferencePolat P, Donofrio PD. Myasthenia gravis induced by nivolumab therapy in a patient with non‐small‐cell lung cancer. Muscle Nerve 2016; 54: 507.
dc.identifier.citedreferenceShirai T, Sano T, Kamijo F et al. Acetylcholine receptor binding antibody‐associated myasthenia gravis and rhabdomyolysis induced by nivolumab in a patient with melanoma. Jpn J Clin Oncol 2016; 46: 86 – 88.
dc.identifier.citedreferenceMandel JJ, Olar A, Aldape KD et al. Lambrolizumab induced central nervous system (CNS) toxicity. J Neurol Sci 2014; 344: 229 – 231.
dc.identifier.citedreferenceKEYTRUDA® (pembrolizumab) [package insert]. Whitehouse Station, NJ: Merck & Co. USA, Inc.; 2015.
dc.identifier.citedreferenceMuro K, Chung HC, Shankaran V et al. Pembrolizumab for patients with PD‐L1‐positive advanced gastric cancer (KEYNOTE‐012): A multicentre, open‐label, phase 1b trial. Lancet Oncol 2016; 17: 717 – 726.
dc.identifier.citedreferenceZimmer L, Goldinger SM, Hofmann L et al. Neurological, respiratory, musculoskeletal, cardiac and ocular side‐effects of anti‐PD‐1 therapy. Eur J Cancer 2016; 60: 210 – 225.
dc.identifier.citedreferenceBoyd K, Kalladka D, Overell J et al. Ipilimumab induced encephalitis: A case report. Immunome Res 2015; 11: 092.
dc.identifier.citedreferenceCarl D, Grüllich C, Hering S et al. Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: A case report. BMC Res Notes 2015; 8: 316.
dc.identifier.citedreferenceConry RM, Sullivan JC, Nabors LB 3rd. Ipilimumab‐induced encephalopathy with a reversible splenial lesion. Cancer Immunol Res 2015; 3: 598 – 601.
dc.identifier.citedreferenceSalam S, Lavin T, Turan A. Limbic encephalitis following immunotherapy against metastatic malignant melanoma. BMJ Case Rep 2016; 2016:pii:bcr2016215012.
dc.identifier.citedreferenceWilliams TJ, Benavides DR, Patrice KA et al. Association of autoimmune encephalitis with combined immune checkpoint inhibitor treatment for metastatic cancer. JAMA Neurol 2016; 73: 928 – 933.
dc.identifier.citedreferenceMaur M, Tomasello C, Frassoldati A et al. Posterior reversible encephalopathy syndrome during ipilimumab therapy for malignant melanoma. J Clin Oncol 2012; 30: e76 – e78.
dc.identifier.citedreferenceLaPorte J, Solh M, Ouanounou S. Posterior reversible encephalopathy syndrome following pembrolizumab therapy for relapsed Hodgkin’s lymphoma. J Oncol Pharm Pract 2017; 23: 71 – 74.
dc.identifier.citedreferenceKhoja L, Maurice C, Chappell M et al. Eosinophilic fasciitis and acute encephalopathy toxicity from pembrolizumab treatment of a patient with metastatic melanoma. Cancer Immunol Res 2016; 4: 175 – 178.
dc.identifier.citedreferenceBloch KC, Glaser C. Diagnostic approaches for patients with suspected encephalitis. Curr Infect Dis Rep 2007; 9: 315 – 322.
dc.identifier.citedreferenceKazandjian D, Suzman DL, Blumenthal G et al. FDA approval summary: Nivolumab for the treatment of metastatic non‐small cell lung cancer with progression on or after platinum‐based chemotherapy. The Oncologist 2016; 21: 634 – 642.
dc.identifier.citedreferencePostow MA, Chesney J, Pavlick AC et al. Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. N Engl J Med 2015; 372: 2006 – 2017.
dc.identifier.citedreferenceTopalian SL, Hodi FS, Brahmer JR et al. Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer. N Engl J Med 2012; 366: 2443 – 2454.
dc.identifier.citedreferenceTopalian SL, Sznol M, McDermott DF et al. Survival, durable tumor remission, and long‐term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol 2014; 32: 1020 – 1030.
dc.identifier.citedreferenceWolchok JD, Kluger H, Callahan MK et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med 2013; 369: 122 – 133.
dc.identifier.citedreferenceUrba WJ, Martin‐Algarra S, Callahan M et al. Immunomodulatory activity of nivolumab monotherapy in patients with advanced melanoma. Paper presented at the AACR Annual Meeting; April 18–22, 2015; Philadelphia, PA.
dc.identifier.citedreferenceWeber JS, Gibney G, Sullivan RJ et al. Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): An open‐label, randomised, phase 2 trial. Lancet Oncol 2016; 17: 943 – 955.
dc.identifier.citedreferenceHodi FS, Chesney J, Pavlick AC et al. Combined nivolumab and ipilimumab versus ipilimumab alone in patients with advanced melanoma: 2‐year overall survival outcomes in a multicentre, randomised, controlled, phase 2 trial. Lancet Oncol 2016; 17: 1558 – 1568.
dc.identifier.citedreferenceAscierto PA, Demidov LV, Garbe C et al. Nivolumab (NIVO) safety in patients with advanced melanoma (MEL) who have progressed on or after ipilimumab (IPI): a single‐arm, open‐label, multicenter, phase II study (CheckMate 172). J Clin Oncol 2016; 34 ( suppl ):9526a.
dc.identifier.citedreferenceChapman PB, Sznol M, Lao C et al. Safety data from an expanded access program (EAP) of nivolumab (NIVO) in combination with ipilimumab (IPI) in patients with advanced melanoma (MEL). J Clin Oncol 2016; 34 ( suppl ): 9525a.
dc.identifier.citedreferenceYang JC, Hughes M, Kammula U et al. Ipilimumab (anti‐CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. J Immunother 2007; 30: 825 – 830.
dc.identifier.citedreferenceBompaire F, Mateus C, Taillia H et al. Severe meningo‐radiculo‐neuritis associated with ipilimumab. Invest New Drugs 2012; 30: 2407 – 2410.
dc.identifier.citedreferenceChampiat S, Lambotte O, Barreau E et al. Management of immune checkpoint blockade dysimmune toxicities: A collaborative position paper. Ann Oncol 2016; 27: 559 – 574.
dc.identifier.citedreferenceHodi FS, O’Day SJ, McDermott DF et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711 – 723.
dc.identifier.citedreferenceLarkin J, Chiarion‐Sileni V, Gonzalez R et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 2015; 373: 23 – 34.
dc.identifier.citedreferenceRobert C, Long GV, Brady B et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 2015; 372: 320 – 330.
dc.identifier.citedreferenceRobert C, Schachter J, Long GV et al. Pembrolizumab versus ipilimumab in advanced melanoma. N Engl J Med 2015; 372: 2521 – 2532.
dc.identifier.citedreferenceWeber JS, D’Angelo SP, Minor D et al. Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti‐CTLA‐4 treatment (CheckMate 037): A randomised, controlled, open‐label, phase 3 trial. Lancet Oncol 2015; 16: 375 – 384.
dc.identifier.citedreferencePostow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015; 33: 1974 – 1982.
dc.identifier.citedreferenceBoutros C, Tarhini A, Routier E et al. Safety profiles of anti‐CTLA‐4 and anti‐PD‐1 antibodies alone and in combination. Nat Rev Clin Oncol 2016; 13: 473 – 486.
dc.identifier.citedreferenceLancaster E. Paraneoplastic disorders. Continuum (Minneap Minn) 2015; 21: 452 – 475.
dc.identifier.citedreferencePignolet BS, Gebauer CM, Liblau RS. Immunopathogenesis of paraneoplastic neurological syndromes associated with anti‐Hu antibodies: A beneficial antitumor immune response going awry. Oncoimmunology 2013; 2: e27384.
dc.identifier.citedreferenceSteinman L. Conflicting consequences of immunity to cancer versus autoimmunity to neurons: Insights from paraneoplastic disease. Eur J Immunol 2014; 44: 3201 – 3205.
dc.identifier.citedreferenceTopalian SL, Sharpe AH. Balance and imbalance in the immune system: Life on the edge. Immunity 2014; 41: 682 – 684.
dc.identifier.citedreferenceHottinger AF. Neurologic complications of immune checkpoint inhibitors. Curr Opin Neurol 2016; 29: 806 – 812.
dc.identifier.citedreferenceYERVOY® (ipilimumab) [package insert]. Princeton, NJ: Bristol‐Myers Squibb Company USA; 2015.
dc.identifier.citedreferenceTarhini A. Immune‐mediated adverse events associated with ipilimumab CTLA‐4 blockade therapy: The underlying mechanisms and clinical management. Scientifica (Cairo) 2013; 2013: 857519.
dc.identifier.citedreferenceLiao B, Shroff S, Kamiya‐Matsuoka C et al. Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma. Neuro Oncol 2014; 16: 589 – 593.
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.